Pregabalin Zentiva

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

pregabalin

Available from:

Zentiva, k.s.

ATC code:

N03AX16

INN (International Name):

pregabalin

Therapeutic group:

Antiepileptici sredstva,

Therapeutic area:

Anxiety Disorders; Epilepsy

Therapeutic indications:

Neuropathic pain , Pregabalin Zentiva is indicated for the treatment of peripheral and central neuropathic pain in adults. , Epilepsy , Pregabalin Zentiva is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation. , Generalised anxiety disorder , Pregabalin Zentiva is indicated for the treatment of generalised anxiety disorder (GAD) in adults.

Product summary:

Revision: 15

Authorization status:

odobren

Authorization date:

2015-07-17

Patient Information leaflet

                                48
B. UPUTA O LIJEKU
49
UPUTA O LIJEKU: INFORMACIJE ZA KORISNIKA
PREGABALIN ZENTIVA 25 MG TVRDE KAPSULE
PREGABALIN ZENTIVA 50 MG TVRDE KAPSULE
PREGABALIN ZENTIVA 75 MG TVRDE KAPSULE
PREGABALIN ZENTIVA 100 MG TVRDE KAPSULE
PREGABALIN ZENTIVA 150 MG TVRDE KAPSULE
PREGABALIN ZENTIVA 200 MG TVRDE KAPSULE
PREGABALIN ZENTIVA 225 MG TVRDE KAPSULE
PREGABALIN ZENTIVA 300 MG TVRDE KAPSULE
pregabalin
PAŽLJIVO PROČITAJTE CIJELU UPUTU PRIJE NEGO POČNETE UZIMATI OVAJ
LIJEK
JER SADRŽI VAMA VAŽNE
PODATKE.
-
Sačuvajte ovu uputu. Možda ćete je trebati ponovno pročitati.
-
Ako imate dodatnih pitanja, obratite se liječniku ili ljekarniku.
-
Ovaj je lijek propisan samo Vama. Nemojte ga davati drugima. Može im
naškoditi, čak i ako su
njihovi znakovi bolesti jednaki Vašima.
-
Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti
liječnika ili ljekarnika. To
uključuje i svaku moguću nuspojavu koja nije navedena u ovoj uputi.
Pogledajte dio
4.
ŠTO SE NALAZI U OVOJ UPUTI
1.
Što je Pregabalin Zentiva i za što se koristi
2.
Što morate znati prije nego počnete uzimati Pregabalin Zentiva
3.
Kako uzimati Pregabalin Zentiva
4.
Moguće nuspojave
5.
Kako čuvati Pregabalin Zentiva
6.
Sadržaj pakiranja i druge informacije
1.
ŠTO JE PREGABALIN ZENTIVA I ZA ŠTO SE KORISTI
Pregabalin Zentiva pripada skupini lijekova koji se koriste za
liječenja epilepsije, neuropatske boli i
generaliziranog anksioznog poremećaja (GAP) u odraslih osoba.
PERIFERNA I CENTRALNA NEUROPATSKA BOL
Pregabalin Zentiva
koristi se za liječenje dugotrajne boli uzrokovane oštećenjem
živaca. Perifernu
neuropatsku bol mogu uzrokovati različite bolesti, primjerice
šećerna bolest ili herpes zoster. Osjet
bola može se opisati kao vrućina, žarenje, pulsirajuća bol,
sijevajuća bol
,
probadanje, oštra bol, grčevi,
stalna tupa bol, trnci, utrnulost, bockanje. Periferna i centralna
neuropatska bol mogu biti povezane s
promjenama raspoloženja, poremećajem spavanja te umorom
(iscrpljenošću), a mogu utjecati na
tjelesno i socijalno funkcioni
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOG I.
SAŽETAK OPISA SVOJSTAVA LIJEKA
2
1.
NAZIV LIJEKA
Pregabalin Zentiva 25 mg tvrde kapsule
Pregabalin Zentiva 50 mg tvrde kapsule
Pregabalin Zentiva 75 mg tvrde kapsule
Pregabalin Zentiva 100 mg tvrde kapsule
Pregabalin Zentiva 150 mg tvrde kapsule
Pregabalin Zentiva 200 mg tvrde kapsule
Pregabalin Zentiva 225 mg tvrde kapsule
Pregabalin Zentiva 300 mg tvrde kapsule
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Pregabalin Zentiva 25 mg tvrde kapsule
Jedna tvrda kapsula sadrži 25 mg pregabalina.
Pomoćna tvar s poznatim učinkom
Jedna
tvrda kapsula također sadrži 47,57
mg laktoza hidrata.
Pregabalin Zentiva 50 mg tvrde kapsule
Jedna tvrda kapsula sadrži 50 mg pregabalina.
Pomoćna tvar s poznatim učink
om
Jedna
tvrda kapsula također sadrži 5
mg laktoza hidrata.
Pregabalin Zentiva 75 mg tvrde kapsule
Jedna tvrda kapsula sadrži 75 mg pregabalina.
Pomoćna tvar s poznatim učinkom
Jedna
tvrda kapsula također sadrži 7,5
mg laktoza hidrata.
Pregabalin Zentiva 100 mg tvrde kapsule
Jedna tvrda kapsula sadrži 100 mg pregabalina.
Pomoćna tvar s poznatim učinkom
Jedna
tvrda kapsula također sadrži 10
mg laktoza hidrata.
Pregabalin Zentiva 150 mg tvrde kapsule
Jedna tvrda kapsula sadrži 150 mg pregabalina.
Pomoćna tvar s poznatim učinkom
Jedna
tvrda kapsula također sadrži 15
mg laktoza hidrata.
Pregabalin Zentiva 200 mg tvrde kapsule
Jedna tvrda kapsula sadrži 200 mg pregabalina.
Pomoćna tvar s poznatim učinkom
Jedna
tvrda kapsula također sadrži 20
mg laktoza hidrata.
Pregabalin Zentiva 225 mg tvrde kapsule
Jedna tvrda kapsula sadrži 225 mg pregabalina.
Pomoćna tvar s poznatim učinkom
Jedna
tvrda kapsula također sadrži 22,5
mg laktoza hidrata.
3
Pregabalin Zentiva 300 mg tvrde kapsule
Jedna tvrda kapsula sadrži 300 mg pregabalina.
Pomoćna tvar s poznatim učinkom
Jedna
tvrda kapsula također sadrži 30
mg laktoza hidrata.
Za cjeloviti popis pomoćnih tvari vidjeti dio
6.1.
3.
FARMACEUTSKI OBLIK
Tvrde kapsule
Pregabalin Zentiva 25 mg tvrde kapsule
Tvrda želatinska kapsula duljine približno 
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 19-03-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 19-03-2024
Public Assessment Report Public Assessment Report Bulgarian 27-07-2015
Patient Information leaflet Patient Information leaflet Spanish 19-03-2024
Public Assessment Report Public Assessment Report Spanish 27-07-2015
Patient Information leaflet Patient Information leaflet Czech 19-03-2024
Public Assessment Report Public Assessment Report Czech 27-07-2015
Patient Information leaflet Patient Information leaflet Danish 19-03-2024
Public Assessment Report Public Assessment Report Danish 27-07-2015
Patient Information leaflet Patient Information leaflet German 19-03-2024
Public Assessment Report Public Assessment Report German 27-07-2015
Patient Information leaflet Patient Information leaflet Estonian 19-03-2024
Public Assessment Report Public Assessment Report Estonian 27-07-2015
Patient Information leaflet Patient Information leaflet Greek 19-03-2024
Public Assessment Report Public Assessment Report Greek 27-07-2015
Patient Information leaflet Patient Information leaflet English 19-03-2024
Public Assessment Report Public Assessment Report English 27-07-2015
Patient Information leaflet Patient Information leaflet French 19-03-2024
Public Assessment Report Public Assessment Report French 27-07-2015
Patient Information leaflet Patient Information leaflet Italian 19-03-2024
Public Assessment Report Public Assessment Report Italian 27-07-2015
Patient Information leaflet Patient Information leaflet Latvian 19-03-2024
Public Assessment Report Public Assessment Report Latvian 27-07-2015
Patient Information leaflet Patient Information leaflet Lithuanian 19-03-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 19-03-2024
Public Assessment Report Public Assessment Report Lithuanian 27-07-2015
Patient Information leaflet Patient Information leaflet Hungarian 19-03-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 19-03-2024
Public Assessment Report Public Assessment Report Hungarian 27-07-2015
Patient Information leaflet Patient Information leaflet Maltese 19-03-2024
Public Assessment Report Public Assessment Report Maltese 27-07-2015
Patient Information leaflet Patient Information leaflet Dutch 19-03-2024
Public Assessment Report Public Assessment Report Dutch 27-07-2015
Patient Information leaflet Patient Information leaflet Polish 19-03-2024
Public Assessment Report Public Assessment Report Polish 27-07-2015
Patient Information leaflet Patient Information leaflet Portuguese 19-03-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 19-03-2024
Public Assessment Report Public Assessment Report Portuguese 27-07-2015
Patient Information leaflet Patient Information leaflet Romanian 19-03-2024
Public Assessment Report Public Assessment Report Romanian 27-07-2015
Patient Information leaflet Patient Information leaflet Slovak 19-03-2024
Public Assessment Report Public Assessment Report Slovak 27-07-2015
Patient Information leaflet Patient Information leaflet Slovenian 19-03-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 19-03-2024
Public Assessment Report Public Assessment Report Slovenian 27-07-2015
Patient Information leaflet Patient Information leaflet Finnish 19-03-2024
Public Assessment Report Public Assessment Report Finnish 27-07-2015
Patient Information leaflet Patient Information leaflet Swedish 19-03-2024
Public Assessment Report Public Assessment Report Swedish 27-07-2015
Patient Information leaflet Patient Information leaflet Norwegian 19-03-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 19-03-2024
Patient Information leaflet Patient Information leaflet Icelandic 19-03-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 19-03-2024

Search alerts related to this product